A phase IIa interferon free combination hepatitis C trial of Simeprevir (TMC435) and TMC647055 will commence shortly

Stockholm, Sweden—Medivir AB (OMX: MVIR), announced today that simeprevir
(TMC435) and TMC647055, a non-nucleoside inhibitor (NNI) will enter a phase IIa
interferon free combination trial.
Simeprevir is a once daily potent HCV NS3/4A protease inhibitor in phase III
clinical development for the treatment of chronic hepatitis C jointly developed
by Medivir and Janssen Research & Development Ireland (Janssen). TMC647055 is a
potent NNI (non-nucleoside inhibitor) of the HCV NS5B polymerase and is being
developed by Janssen R&D.

“This study is in line with Medivir’s and Janssen’s strategy to evaluate
different combination possibilities with simeprevir for interferon-free HCV
treatments. This will broaden our understanding of simeprevir, which we believe
has the necessary characteristics to potentially become a key component of
future hepatitis C treatment regimens, including combination with interferon and
ribavirin as well as interferon-free therapies,” comments Charlotte Edenius,
Medivir’s EVP of Research and Development.

Study design
This will be an open label study in patients who are chronically infected with
HCV genotype-1a or 1b to assess the efficacy, safety and tolerability of the
combination. The primary endpoint in the study will be SVR12 (sustained
virologic response 12 weeks after end of treatment). Simeprevir, TMC647055 and
low-dose ritonavir will be co-administered once daily, with and without
ribavirin.

Approximately 40 patients will be enrolled in this study, which is divided in
two parts. The first part will include patients chronically infected with HCV
genotype-1, who are either treatment-naive or have relapsed after prior
pegylated interferon (PegIFN)/ribavirin treatment. The treatment will consist of
simeprevir, TMC647055 and low-dose ritonavir, with and without ribavirin for 12
weeks.

The second part of the trial will investigate the same regimen in prior null
responder patients chronically infected with HCV genotype 1a.

Additional information about this study will be posted on www.clinicaltrials.gov

For more information about Medivir, please contact:

Medivir                      Direct: +46 8 440 6550
Rein Piir, EVP Corporate     or: Mobile:
Affairs & IR                 +46 708 537 292
M:Communications             medivir@mcomgroup.com
Europe: Mary-Jane Elliott,   +44(0)20 7920 2330
Amber Bielecka, Hollie Vile

About Medivir
Medivir is an emerging research-based pharmaceutical company focused on
infectious diseases. Medivir has world class expertise in polymerase and
protease drug targets and drug development which has resulted in a strong
infectious disease R&D portfolio. The Company’s key pipeline asset is simeprevir
(TMC435), a novel protease inhibitor in phase III clinical development for
hepatitis C that is being developed in collaboration with Janssen Research &
Development Ireland

In June 2011, Medivir acquired the specialty pharmaceutical company BioPhausia.
and today Medivir has a broad product portfolio with prescription
pharmaceuticals in the Nordics.

Medivir’s first product, the unique cold sore product Xerese®/Xerclear®, is
launched in collaboration with GlaxoSmithKline to be sold OTC under the brand
name ZoviDuo in Europe, Japan and Russia.

Medivir’s IPO was in 1996 and currently the company has around 180 employees.

For more information about Medivir, please visit the Company’s website:
www.medivir.com